These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW. Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166 [Abstract] [Full Text] [Related]
4. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin]. Liu ZJ, Wei H, Duan LP, Zhu SW, Zhang L, Wang K. Zhonghua Yi Xue Za Zhi; 2016 Jun 28; 96(24):1896-902. PubMed ID: 27373356 [Abstract] [Full Text] [Related]
12. Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. Furnari M, Savarino E, Bruzzone L, Moscatelli A, Gemignani L, Giannini EG, Zentilin P, Dulbecco P, Savarino V. J Gastrointestin Liver Dis; 2012 Jun 22; 21(2):157-63. PubMed ID: 22720304 [Abstract] [Full Text] [Related]
13. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A. Eur Rev Med Pharmacol Sci; 2013 May 22; 17(10):1314-20. PubMed ID: 23740443 [Abstract] [Full Text] [Related]